International Patent Protection — PCT, Paris Convention & Patent Filing Strategy

A U.S. patent protects an invention only in the United States — it provides no protection against manufacturers or sellers in Germany, China, Japan, or any other foreign country. For businesses that sell or license products internationally, or that manufacture overseas and want to prevent foreign competition from copying their technology, obtaining patent protection in key foreign markets is essential. For the domestic patent law these international filings build on, see patent law. Two legal frameworks govern how U.S. inventors and businesses pursue international patent protection:

1. The Paris Convention (1883, 168 signatory countries): A bilateral treaty framework allowing inventors who file a patent application in their home country to claim that filing date as the "priority date" in other member countries — if they file in those countries within 12 months of the original filing.

2. The Patent Cooperation Treaty (PCT) (1970, 157 signatory countries, administered by WIPO): A centralized international filing system allowing inventors to file a single "international application" that simultaneously reserves rights in all PCT member countries, with a 30-month window (from the priority date) to enter national or regional phases in chosen countries.

These frameworks are implemented in U.S. law through 35 U.S.C. §§ 119-120 (priority claims) and 35 U.S.C. §§ 361-390 (PCT), and they work together — most international patent strategies use both: a U.S. application establishes the priority date, PCT filing is done within 12 months of the U.S. priority date (extending the deadline for national-phase entry to 30 months from the priority date), and national/regional phase entries in key markets follow.

Current Law (2026)

Legal Authority

• 35 U.S.C. § 119(a) — Right of priority: an application filed in the U.S. by a national or resident of a Paris Convention country may claim the benefit of the filing date of a corresponding application filed in that country, provided the U.S. application is filed within 12 months of the foreign application
• 35 U.S.C. § 120 — Benefit of earlier U.S. filing date: a later-filed U.S. application can claim the filing date of an earlier U.S. application for prior art and priority purposes (continuation, continuation-in-part, divisional)
• 35 U.S.C. § 363 — International application designating U.S.: an international application designating the United States shall have the effect of a regular U.S. application on the international filing date
• 35 U.S.C. § 365 — Right of priority: an international application shall be entitled to the right of priority of a prior foreign application in the same manner as permitted by 35 U.S.C. § 119
• 35 U.S.C. § 371 — National stage commencement: a person who has filed a PCT international application designating the U.S. may comply with national stage requirements by paying fees, filing translation if needed, and submitting the application — national stage commences upon completion of these requirements
• 35 U.S.C. § 374 — Publication: international applications designating the U.S. are published as U.S. patent applications upon national stage entry or 18 months after filing, whichever is earlier
• 35 U.S.C. § 376 — Fees: national stage applicants pay standard USPTO fees upon entering the national phase; international filing fees are paid to the receiving office and distributed to WIPO

The International Patent Filing Framework

The Priority Date — The Foundation of International Patent Strategy

Under the Paris Convention, when you file a patent application in any member country, you establish a priority date. If you then file corresponding applications in other member countries within 12 months of that priority date, those later-filed applications are treated as if they were filed on the priority date — meaning prior art and competing filings that appear during that 12-month window don't count against you.

Why priority dates matter:

• They determine which prior art can defeat your patent — prior art must predate your priority date
• They govern who wins in first-to-file priority disputes between competing applicants
• They are the starting point for calculating the 30-month PCT national phase deadline

Practical strategy: Most U.S. applicants file a U.S. provisional application first ($330 filing fee for small entities), which establishes a priority date with minimal cost and formality, then file a full U.S. nonprovisional application within 12 months (which can claim the provisional's priority date) and simultaneously file a PCT application — using the same priority date — to begin the international process.

The Patent Cooperation Treaty (PCT) Process

The PCT allows a single international application to simultaneously reserve rights in 157 countries. The PCT does not grant international patents — patents are still granted by individual countries — but it provides a centralized international phase that delays (and often reduces) the cost and complexity of national patent prosecution.

Step 1: International Application Filing The applicant files a PCT application with a Receiving Office (USPTO for U.S. applicants, or directly with WIPO). The application must be filed within 12 months of the priority date to claim priority. Filing fees include: an international filing fee to WIPO ($1,330 for first 30 pages + per-page charges), a search fee to the International Searching Authority ($2,080 if the USPTO is the ISA), and a transmittal fee to the Receiving Office.

Step 2: International Search Report (ISR) and Written Opinion (WO) The designated International Searching Authority (ISA) — which for U.S. applications can be the USPTO, EPO, or other authorized offices — searches for relevant prior art and issues an International Search Report (ISR) and Written Opinion (WO) on patentability. The ISR and WO are published by WIPO approximately 16 months after the priority date. They are not binding — national offices make their own patentability determinations — but they signal how the application is likely to be received and allow the applicant to amend claims before national phase entry.

Step 3: International Publication WIPO publishes the international application (including the ISR) approximately 18 months after the priority date, in one of the PCT languages. Publication is automatic; applicants cannot prevent it after 18 months (though they can request early publication).

Step 4: Optional International Preliminary Examination Applicants may request International Preliminary Examination (IPEA) by an authorized authority (USPTO, EPO, etc.), which produces a non-binding opinion on novelty, inventive step, and industrial applicability. This costs additional fees but can help applicants refine their claims before national phase entry, and may provide some persuasive authority in national phase prosecution.

Step 5: National Phase Entry (30-Month Deadline) The applicant must enter the national phase in each desired country within 30 months of the priority date (some countries require entry by 20 months; most have adopted the 30-month standard). National phase entry requires:

• Paying national/regional filing fees in each jurisdiction
• Filing a translation if the application is not in the country's official language
• Complying with local procedural requirements

From this point, each national patent office examines the application under its own laws. A patent in Germany is examined by the German Patent and Trade Mark Office; a European patent is examined by the EPO; a Chinese patent by CNIPA (China National Intellectual Property Administration). Each jurisdiction has its own prosecution timeline, typically taking 2-5 years.

Regional Patent Systems

Rather than filing separately in each European country, applicants can file a single European patent application at the European Patent Office (EPO) under the European Patent Convention (EPC). If granted, the European patent can be validated in up to 38 EPC member countries (EU members plus Switzerland, Norway, UK, etc.) by filing translations (in some countries) and paying validation fees. The Unitary Patent system (launched June 2023) further simplifies this — a single Unitary Patent covers 17 EU member states (and growing) with a single validation, single renewal fee, and unified post-grant enforcement framework.

Other regional systems include:

• ARIPO (African Regional Intellectual Property Organization) — Eastern Africa
• OAPI (Organisation Africaine de la Propriété Intellectuelle) — West/Central Africa (French-speaking)
• EAPO (Eurasian Patent Organization) — Former Soviet states
• GCC Patent Office — Gulf Cooperation Council countries

Countries NOT in PCT

A few commercially significant jurisdictions are not PCT members, requiring direct national filing:

• Taiwan — not a PCT member (file directly with Taiwan Intellectual Property Office)
• Argentina — technically not participating in all PCT procedures; direct filing often preferred
• Most smaller jurisdictions follow national filing requirements

How It Affects You

If you're an individual inventor or small startup with a promising product: The PCT's 30-month window is your most important strategic tool — it gives you 18 additional months beyond the 12-month Paris Convention period to decide which foreign markets to pursue, without losing your priority date. This extra time allows you to: test market reception, find licensees, raise funding, and better estimate the value of foreign protection before committing to the significant cost (~$5,000-$30,000 per country depending on patent office fees, translation costs, and attorney fees). A realistic budget for international patent protection in 5-6 major markets (U.S. national phase, EPO/Europe, China, Japan, South Korea, Canada) is $50,000-$150,000 through grant in all jurisdictions. This is why most small inventors limit international protection to 2-3 markets where they believe the commercial opportunity most justifies the investment. Filing a PCT application does not commit you to entering any national phase — you can let the PCT application lapse at 30 months without penalty if you decide foreign protection isn't worth the cost.

If you're a technology company with a significant product line: International patent strategy should align with your commercial and competitive strategy. Key questions: Where do you sell? (Protect in key markets.) Where do competitors manufacture? (Consider protection in manufacturing countries to prevent competing production.) Where do your customers operate? (Protect where you license to customers.) Filing PCT applications as a routine part of product development — for key innovations, not every incremental improvement — is standard practice for technology companies with meaningful R&D investment. EPO prosecution provides European coverage efficiently; China filing (through CNIPA) is increasingly essential as Chinese manufacturers have become major competitors. Patent portfolio audits should periodically identify which foreign patents are worth their annual maintenance costs and which can be abandoned.

If you license technology or are considering a cross-licensing deal: Foreign patent rights are separate assets from U.S. patents — they must be licensed separately unless the agreement explicitly includes foreign rights. In licensing negotiations, the geographic scope of a license is a key term: "worldwide" licenses include both U.S. and foreign patent rights; "U.S. only" licenses exclude them. PCT applications that have entered national phase become separate national/regional patents, each of which must be addressed in a licensing agreement. For companies negotiating cross-licenses (trading patent portfolios with competitors to avoid litigation), the strength and geographic coverage of each party's portfolio in key markets matters significantly — a strong U.S. patent position paired with minimal foreign protection is a weaker negotiating position than balanced global coverage.

If you're evaluating whether a competitor's product infringes your patents: U.S. patent rights end at the U.S. border. A foreign manufacturer who makes and sells products only outside the U.S. does not infringe a U.S. patent (though they may infringe if they import into the U.S.). If a competitor manufactures abroad and imports into the U.S., both the importer and the product are subject to U.S. patent infringement claims — see the International Trade Commission's Section 337 investigation authority, which can result in exclusion orders blocking importation of infringing goods. For infringement occurring entirely in foreign countries, you need the corresponding foreign patent rights to bring infringement claims.

State Variations

International patent protection is entirely federal (and international treaty) — states have no role in patent grants. However, state contract law governs:

• Licensing agreements for international patent rights (choice of law provisions in international licenses matter)
• Employment agreements assigning international patent rights to employers (state law governs assignment enforceability in some respects, particularly for California employees — California Labor Code § 2870 limits employers' ability to claim inventions made outside employment duties)

Recent Developments

• 2023 — EU Unitary Patent launched: The Unitary Patent and Unified Patent Court (UPC) system entered into force June 1, 2023, offering a single patent enforceable across 17 EU member states (with more expected to join) and a unified court system for patent disputes. This is the most significant change to European patent practice in decades — applicants can now request unitary effect for granted European patents, avoiding the need to validate separately in each country. The UPC also allows central revocation of unitary patents, which is a new risk for patent holders.
• 2023 — China patent term extension: China implemented patent term extension (PTE) for pharmaceutical patents (consistent with its CPTPP commitments), allowing patent term restoration for regulatory review delays — aligning Chinese pharmaceutical patent practice more closely with U.S. and European practice.
• 2024 — AI and inventorship (international dimension): While the U.S. (and most countries) require a human inventor, there are developing differences in how countries treat AI-assisted inventions and the thresholds for "significant contribution." UK and Australian courts have addressed the Thaler/DABUS cases differently than U.S. courts, creating uncertainty for AI-related international filings.
• 2024 — PCT fee changes: WIPO updated PCT international filing fees, with reductions for certain applicant types (micro entities, developing country applicants). Fee structures continue to be adjusted to encourage broader global participation in the patent system.
• 2025 — China IP enforcement improvements: China continued implementing reforms to its IP enforcement system, including expanded damages, specialized IP courts in major cities, and strengthened customs enforcement — though concerns about the enforcement environment for foreign patent holders remain. China is now the world's largest PCT filer, with Chinese companies filing more PCT applications than any other country.
• 2025-2026 — CHIPS Act and semiconductor patents: The CHIPS and Science Act's domestic semiconductor manufacturing incentives intersect with international patent strategy — companies establishing U.S. manufacturing under CHIPS Act grants must navigate export control restrictions that interact with technology licensing and patent prosecution in China and other restricted countries.